Clinical and molecular hepatology
ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling.
Baorui Tao, Chenhe Yi, Bo Zhang, Yan Geng, Yinchen Gu, Rongquan Sun, Xiangyu Wang, Jing Lin, Jinhong Chen
Published: 202610.3350/cmh.2025.0972
Abstract
Background/Aims: Regorafenib is recommended by guidelines and trials as a sequential second-line therapy following progression on first-line sorafenib or lenvatinib in hepatocellular carcinoma (HCC). However, efficacy is limited, highlighting the urg…
Preview only. Read the full abstract at the source